41 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:29am
and forecasting of our environmental data and performance, embed sustainability principles into the lifecycle of our therapies and build resilience
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:24am
in lifecycle management programs. In rare hematology, Takeda focuses on addressing today’s needs in the treatment of bleeding disorders, including through
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
TAKHZYRO, with continued investment in lifecycle management programs. In rare hematology, Takeda focuses on addressing today’s needs in the treatment
6-K
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
, including through TAKHZYRO, with continued investment in lifecycle management programs. In rare hematology, Takeda focuses on addressing today’s needs
6-K
TAK
Takeda Pharmaceutical Co
1 Aug 23
Current report (foreign)
6:10am
, Takeda aspires to transform the treatment paradigm, including through TAKHZYRO, with continued investment in lifecycle management programs. In rare
6-K
EX-99.1
xuvr tyxkjezot
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
1dowjg2n
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
pvguyp 9nfhtj7a2
30 May 23
Current report (foreign)
6:11am
6-K
gchss3
4 Nov 22
Current report (foreign)
6:01am
6-K
n46umff7wpu 7o0bztg
4 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
thxiwcc3bdpfg zh
31 May 22
Current report (foreign)
6:14am
6-K
EX-99.1
9h8k x045ixp
31 May 22
Current report (foreign)
6:07am
6-K
qfxs29x
11 May 22
Current report (foreign)
6:06am
6-K
rcqpf
10 Feb 22
Current report (foreign)
6:03am
6-K
EX-99.1
2qj38zq emthy
11 Jan 22
Current report (foreign)
6:02am
6-K
qq9ffjb
5 Nov 21
Current report (foreign)
6:02am
6-K
yb3iygypnk
6 Aug 21
Current report (foreign)
6:06am
6-K
EX-99.1
980k8fidye1 jjnb
29 Jun 21
Current report (foreign)
7:38am